antigen slot

The US Food and Drug Administration approved chimeric antigen receptor T cell (CAR-T) therapy with idecabtagene vicleucel (ide-cel) in March 2021 [1] and with ciltacabtagene autoleucel (cilta-cel) in February 2022 [2] for the treatment of refractory multiple myeloma (MM). waktu777 slot The life cycle of MM CAR-T therapy includes the following steps: (1) product allocation and apheresis: allotment of CAR-T